Cognition Therapeutics Reaches Full Enrollment in Zervimesine Expanded Access Program for Dementia with Lewy Bodies
I'm PortAI, I can summarize articles.
Cognition Therapeutics Inc. has achieved full enrollment in its expanded access program for zervimesine (CT1812) for dementia with Lewy bodies. Participants will receive a daily 100 mg dose for up to a year. The program, funded by a donation, completed enrollment in three months. A Type C meeting with the FDA is scheduled for January to discuss a Phase 3 program. No new scientific results were announced.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments